Effect of Adalimumab on Refractory Arthritis in Juvenile Idiopathic Inflammatory Myopathy with Anti-MDA5 Autoantibody

Figure 2

Radiography of both hands. (a) In September 2014, at the initiation of adalimumab when the patient was 12 years and 1 month of age. (b) In September 2016, after 2 years of adalimumab treatment when the patient was 14 years and 1 month of age. Narrowing of the metacarpophalangeal joints of both index fingers was observed when adalimumab was started (a), and more progressive joint space narrowing existed under treatment with adalimumab, whereas insignificant bone erosion was observed (b).

(a)

(b)